Close Menu

NEW YORK – In a document filed with the US Securities and Exchange Commission on Thursday, Abbott Laboratories said it had entered a five-year, $5 billion revolving credit agreement with JP Morgan Chase as the administrative agent.

Under the agreement, Abbott can borrow up to $5 billion on an unsecured basis and any borrowings will mature and be payable five years from the effective date, Nov. 12, 2020. The borrowings will bear interest based on either a base rate or a Eurodollar rate, the filing said. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.